The manufacturer of the experimental AIDS drug GS 9137 Gilead Sciences Inc. has revealed that the results of the drug experiments were successful, as lower levels of HIV were noticed in the case of those who were taking the treatment. The experiment was conducted over a period of 10 days on 40 patients.
The negative side effects were also not seen to be of a serious nature. This new therapy is of the integrase inhibitors class which contributes towards preventing the virus from replicating itself. The new drug targets a weak point of the HIV which does not change its shape and evade treatment. The HIV's integrase comes under attack by the new drug which enables the merging of the virus with the human DNA.
The drug appears to be effective even in the case of patients whose virus has attained immunity to other medicines. An FDA approval for the drug will be sought by Merck in the year 2007.